For at opnå vedvarende terapeutisk respons bør behandlingen dog ikke afbrydes, før det forventede nadir er passeret, og neutrofiltallet er normaliseret.
However, for a sustained therapeutic response, filgrastim therapy should not be discontinued before the expected nadir has passed and the neutrophil count has recovered to the normal range.